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During the progression of diabetes, crosstalk between ER stress and inflammation controls islet cell fate. In
this issue, Lerner et al. (2012) and Oslowski et al. (2012) discover that thioredoxin-interacting protein (TXNIP)
is a regulatory switch connecting the terminal unfolded protein response (UPR) and NLRP3 inflammasome to
mediate b cell death.Excessive or protracted inflammation trig-
gered by a chronic accumulation of meta-
bolic factors is a hallmark of many degen-
erative diseases, including both type 1
and type 2 diabetes. Inflammation is the
first means by which the immune system
limits cell injury and damage in response
to environmental irritants, pathogens, and
infectious agents. Yet left unchecked, the
inflammatory process turns toward cel-
lular destruction and pyroptosis, a form
of programmed cell death dependent on
caspase-1 activation and proinflamma-
tory cytokines. How the inflammatory
process switches from stress remediation
toward death pathways is a mystery.
Recently, efforts directed at mechanisms
linking metabolic overload with self-
destruction and diabetes progression
have discovered that uncontrolled endo-
plasmic reticulum (ER) stress is associ-
ated with a sterile but lethal inflammatory
response (Hummasti and Hotamisligil,
2010). Themolecular connection between
these two biological responses, now
identified in this issue, is thioredoxin-in-
teracting protein (TXNIP) (Lerner et al.,
2012; Oslowski et al., 2012).
Oxidative stress disrupts ER homeo-
stasis, activating a multifaceted signaling
program called the unfolded protein re-
sponse (UPR). Three transmembrane sen-
sors, namely inositol-requiring enzyme
1 (IRE1), PKR-like ER-resident kinase
(PERK), and activating transcription factor
6 (ATF6) together elicit a program of gene
expression designed to alleviate a build-
up of misfolded proteins and regain ER
homeostasis. Hyperactivation of the UPR
to irremediable ER stress leads to inflam-
mation and cell death, and in the case of
the b cell, culminates in diabetes. In the
current articles (Lerner et al., 2012;Oslow-ski et al., 2012), two of the three UPR
sensors, namely IRE1a and PERK, play
critical roles in regulating the expression
of TXNIP. Treatment with pharmacologic
agents that cause ER stress increased
TXNIP mRNA levels in wild-type and
ATF6/ mouse embryonic fibroblasts
but not in cells deficient for IRE1a or
PERK (Lerner et al., 2012; Oslowski
et al., 2012). Similarly, siRNA-mediated
knockdown of IRE1a or PERK, but not
ATF6, in insulinomacells precludedTXNIP
mRNA expression following ER stress
(Oslowski et al., 2012). The lack of ATF6
involvement in regulating TXNIP expres-
sion emphasizes that the relationship
between ER stress and inflammation
occurs independent of the tripartite UPR.
These findings are significant in that
each sensor can have distinct functions
implementing the UPR, with IRE1a and
PERK each participating in cell destruc-
tion during unabated stress.
Urano and colleagues (Oslowski et al.,
2012) then went further to identify the
PERK-regulated transcription factors
controlling TXNIP expression. During ER
stress, PERK phosphorylates eukaryotic
initiation factor 2 (eIF2), reducing global
translation. This action lowers the influx
of proteins into the ER and directs energy
toward preferentially translating select
mRNAs, such as ATF4, which promotes
the expression of genes controlling redox
status plus facilitates induction of the
other arms of the UPR (Teske et al.,
2011). However, following a screen of
transcription factors regulated by PERK,
it was concluded that ATF4 was not
a significant regulator of TXNIP synthe-
sis. Rather, a related transcription factor
called ATF5, also subject to translational
control by eIF2 phosphorylation, wasCell Metabolism 1shown via chromatin immunoprecipita-
tion analysis to bind the TNXIP promoter
during ER stress. These data demonstrate
that the PERK arm of the UPR functions
primarily to increase TXNIP transcription
during ER stress.
The contribution of IRE1a in the regula-
tion of TXNIP expression depends on its
dual functions as both a protein kinase
and an endoribonuclease. Upon remedi-
able ER stress, IRE1a kinase domain
is autophosphorylated, restricting its
carboxy-terminal ribonuclease activity
toward the mRNA encoding XBP-1
(X-box-binding protein 1). This splicing
event produces a potent transcription
factor that is important for triggering
adaptive functions such as ER-to-Golgi
protein transport, protein folding, and
ER-associated degradation (ERAD) of
misfolded proteins. Under conditions of
irremediable ER stress, IRE1a ribonu-
clease activity becomes less discriminate
(Han et al., 2009), and as described in this
issue (Lerner et al., 2012), triggers decay
of mi-R17, a regulator of TXNIP mRNA
stability. Under normal conditions, TXNIP
mRNA half-life is short, but during ER
stress it becomes stabilized. Increased
mRNA stability alone can lead to elevated
mRNA expression, but when combined
with PERK-mediated increase in tran-
scription, a steeper induction results (Fig-
ure 1). This finding extends previous work
by this group and others (Han et al., 2009;
Hollien et al., 2009) by showing how
IRE1a-dependent decay of mi-R17 tailors
the transcriptome to ER stress. To vali-
date these concepts in vivo, islets from
the ‘‘Akita’’ mouse (Ins2WT/C96Y), a model
of diabetes caused by proinsulin mis-
folding, demonstrated reduced mi-R17
and elevated TXNIP mRNA. Furthermore,6, August 8, 2012 ª2012 Elsevier Inc. 135
Figure 1. TXNIP Serves as the Wye Switch that Redirects b Cell Cell Fate from an Adaptive to Terminal UPR
b cells can encounter physiological conditions leading to low remediable ER stress (blue) or hyperactivated ER stress that is irremediable (red). These stress
signals are recognized by ER-resident proteins IRE1a and PERK, which signal elevated expression of TXNIP. Elevated TXNIP levels during hyperactivated stress
directs the wye switch for cell fate, leading to a terminal UPR, featuring activation of the inflammasome and pyroptosis.
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Previewspancreatic islets from TXNIP/ mice
showed reduced cell death in response
to ER stress agents and genetic dele-136 Cell Metabolism 16, August 8, 2012 ª201tion of TXNIP in Akita mice protected
them from hyperglycemia (Lerner et al.,
2012). This study reveals that regulated2 Elsevier Inc.mRNA stability of TXNIP contributes
importantly to cell fate decisions during
ER stress.
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PreviewsChronic excess of metabolic factors
(e.g., glucose, lipids) promotes formation
of large, multiprotein complexes called in-
flammasomes. NOD-like receptor (NLR)
proteins are key components of inflam-
masomes, facilitating caspase-1 matura-
tion and secretion of cytokines in re-
sponse to cellular danger (Schroder
et al., 2010; Vandanmagsar et al., 2011).
The NLRP3 inflammasome in particular
functions as a sensor of metabolic stress
activated by high glucose and reactive
oxygen species (ROS) (Zhou et al.,
2010). Thanks to the current studies
(Lerner et al., 2012; Oslowski et al.,
2012), the relationship between ER stress
and the inflammasome is now clarified.
With increased levels of TXNIP, the
antioxidant function of thioredoxins are
dampened, further increasing ROS, and
binding of TXNIP to NLRP3 is promot-
ed, activating caspase-1 cleavage, inter-
leukin (IL)-1b secretion and pyroptosis.
In support of this, inducing TXNIP expres-
sion increased caspase-3 cleavage and
cell death in insulinoma cells, and pre-
treating human primary islets with IL-1
receptor antagonist reduced IL-1b andIL-6 expression and caspase-3/-7 activity
to ER stress agents (Oslowski et al.,
2012). TXNIP is therefore suggested
to serve as a wye switch that can redi-
rect the cell-fate railway track from an
adaptive outcome to a terminal UPR
(Figure 1).
Human conditions such as Wolfram
syndrome type 1 ascribe loss of b cells
to unmitigated ER stress and activation
of the UPR. Significant levels of ER stress
in b cells can also be the consequence of
continued exposure to free fatty acids and
cytokines (Hummasti and Hotamisligil,
2010). By identifying a novel path in the
pathogenesis of diabetes, the current
studies are foundational to the develop-
ment of new treatment approaches. Im-
portantly, Lerner et al. (2012) show that
a drug that inhibits IRE1a endoribonu-
clease activity without affecting its kinase
activity (STF-083010) reduces TXNIP ex-
pression and inflammasome activation
in b cells. It is hopeful that this or other
novel small-molecule inhibitors of this
pathway can be tailored toward the treat-
ment of diabetes and/or other degenera-
tive diseases.Cell Metabolism 1REFERENCES
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The opioid system plays a pivotal role in how our brain regulates hedonic components of ingestive behavior.
Duraffourd et al. (2012) add the gut to this opioid landscape, demonstrating direct activation of periportal
m-opioid receptors by food-derived opioid peptides (nutropioids), and a gut-brain feedback spiral that culmi-
nates in enhanced satiety.For centuries, everybody—from choco-
late lovers to steak aficionado—has
agreed on the addictive reward of certain
foods. In fact, ‘‘food cravings’’ have
been shown to override even the stron-
gest homeostatic drive. Their neuroana-
tomical and molecular underpinnings
suggest striking similarities with central
opioidergic mechanisms previously iden-
tified to mediate classic drug addictions.Accordingly, opioid receptors in the brain
have been shown to orchestrate multiple
hedonic components of ingestive be-
havior. An elegant study recently pub-
lished in Cell now also introduces the gut
as a potential control center for opioid
response circuits regulating food intake
(Duraffourd et al., 2012).
Opioid control of food intake has
been studied for several decades. Endog-enous opioid peptides such as endor-
phinswere first identified in 1975 (Hughes,
1975). Today, the current model suggests
that opioid signaling, especially via the
m-opioid receptor (MOR), is a major
driver of both the ‘‘wanting’’ (i.e., incentive
motivation and appetite) and ‘‘liking’’
(i.e., pleasure and palatability) aspects of
ingestive behavior. ‘‘Nutropioids,’’ i.e.,
opioid oligopeptides derived from food,6, August 8, 2012 ª2012 Elsevier Inc. 137
